NASDAQ:YMAB Y-mAbs Therapeutics - YMAB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.55 -0.13 (-2.78%) (As of 02/6/2023 04:10 PM ET) Add Compare Share Share Today's Range$4.51▼$4.7550-Day Range$4.18▼$5.1852-Week Range$2.94▼$20.48Volume170,746 shsAverage Volume325,373 shsMarket Capitalization$198.70 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Y-mAbs Therapeutics MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside207.7% Upside$14.00 Price TargetShort InterestHealthy5.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 6 Articles This WeekInsider TradingAcquiring Shares$5,879 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.73) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.51 out of 5 starsMedical Sector118th out of 1,027 stocksPharmaceutical Preparations Industry49th out of 500 stocks 4.1 Analyst's Opinion Consensus RatingY-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 4 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Y-mAbs Therapeutics has a forecasted upside of 207.7% from its current price of $4.55.Amount of Analyst CoverageY-mAbs Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.47% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently decreased by 0.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YMAB. Previous Next 1.9 News and Social Media Coverage News SentimentY-mAbs Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Y-mAbs Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 3 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,879.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.61% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.96% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($2.73) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Y-mAbs Therapeutics (NASDAQ:YMAB) StockY-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.Read More Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Stock News HeadlinesJanuary 25, 2023 | marketbeat.comHow Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (YMAB)Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.February 6, 2023 | benzinga.comY-mAbs Shareholder Action ReminderFebruary 6, 2023 | Investing Trends (Ad)"TAKE THAT, CHINA!" USA Gains in EV Battery Arms RaceDid you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution. February 3, 2023 | benzinga.comYMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud LawsuitFebruary 2, 2023 | finance.yahoo.comY-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for NaxitamabFebruary 1, 2023 | wsj.comNOTICE: Investors in Y-mAbs Therapeutics, Inc. with Significant Losses Have Opportunity to Lead Securities Class Action Lawsuit - YMABFebruary 1, 2023 | wsj.comNOTICE: Investors in Y-mAbs Therapeutics, Inc. with Significant Losses Have Opportunity to Lead Securities Class Action Lawsuit - YMABFebruary 1, 2023 | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) PT Raised to $13.00February 6, 2023 | Investing Trends (Ad)"TAKE THAT, CHINA!" USA Gains in EV Battery Arms RaceDid you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution. January 30, 2023 | americanbankingnews.comMorgan Stanley Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) to UnderweightJanuary 27, 2023 | wsj.comY-mAbs Shareholder NoticeJanuary 27, 2023 | benzinga.comY-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.January 27, 2023 | morningstar.comNOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMABJanuary 27, 2023 | wsj.comYMAB INVESTOR ALERT: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 25, 2023 | wsj.comY-mAbs Therapeutics Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More InformationJanuary 24, 2023 | benzinga.comY-mAbs Therapeutics, Inc. (YMAB) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Y-mAbs Therapeutics, Inc.January 24, 2023 | wsj.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the FirmJanuary 24, 2023 | wsj.comNOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit -- YMABJanuary 23, 2023 | benzinga.comYMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors Of a Class Action Lawsuit and Upcoming DeadlineJanuary 23, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) InvestorsJanuary 23, 2023 | benzinga.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the FirmJanuary 21, 2023 | markets.businessinsider.comINVESTOR DEADLINE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - YMABJanuary 20, 2023 | technews.tmcnet.comShareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)January 20, 2023 | benzinga.comBronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively ParticipateJanuary 20, 2023 | technews.tmcnet.comKirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) InvestorsJanuary 19, 2023 | benzinga.comY-mAbs Investor AlertJanuary 19, 2023 | technews.tmcnet.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of InvestorsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Company Calendar Last Earnings11/04/2021Today2/06/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:YMAB CUSIPN/A CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees148Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$27.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+207.7%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,280,000.00 Net Margins-307.75% Pretax Margin-307.75% Return on Equity-92.65% Return on Assets-74.97% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio3.97 Sales & Book Value Annual Sales$34.90 million Price / Sales5.69 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book1.10Miscellaneous Outstanding Shares43,670,000Free Float34,668,000Market Cap$198.70 million OptionableNot Optionable Beta0.70 Key ExecutivesThomas GadPresident, Chief Executive Officer & DirectorJoris Wiel Jan WilmsChief Operating Officer & Senior Vice PresidentBo KruseCFO, Secretary. Treasurer & Executive VPTorben Lund-HansenChief Technology Officer & Senior Vice PresidentSteen LisbyChief Scientific Officer & Senior Vice PresidentKey CompetitorsProQR TherapeuticsNASDAQ:PRQRVerrica PharmaceuticalsNASDAQ:VRCACitius PharmaceuticalsNASDAQ:CTXRPuma BiotechnologyNASDAQ:PBYINature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCSold 6,483 shares on 2/2/2023Ownership: 0.023%Rice Hall James & Associates LLCSold 3,575 shares on 1/27/2023Ownership: 0.199%Strs OhioBought 80,800 shares on 1/26/2023Ownership: 0.252%Bank of New York Mellon CorpBought 10,698 shares on 12/8/2022Ownership: 0.260%Jane Street Group LLCBought 12,375 shares on 11/16/2022Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions YMAB Stock - Frequently Asked Questions Should I buy or sell Y-mAbs Therapeutics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares. View YMAB analyst ratings or view top-rated stocks. What is Y-mAbs Therapeutics' stock price forecast for 2023? 11 brokerages have issued twelve-month target prices for Y-mAbs Therapeutics' stock. Their YMAB share price forecasts range from $4.00 to $27.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 207.7% from the stock's current price. View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts. How have YMAB shares performed in 2023? Y-mAbs Therapeutics' stock was trading at $4.88 at the beginning of the year. Since then, YMAB shares have decreased by 6.8% and is now trading at $4.55. View the best growth stocks for 2023 here. When is Y-mAbs Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our YMAB earnings forecast. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.08. The firm earned $8.97 million during the quarter, compared to analyst estimates of $10.87 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 92.65% and a negative net margin of 307.75%. During the same quarter in the previous year, the firm earned ($0.82) earnings per share. What guidance has Y-mAbs Therapeutics issued on next quarter's earnings? Y-mAbs Therapeutics issued an update on its FY 2022 earnings guidance on Monday, November, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $51.75 million. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN). When did Y-mAbs Therapeutics IPO? (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. What is Y-mAbs Therapeutics' stock symbol? Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB." Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Strs Ohio (0.25%), Rice Hall James & Associates LLC (0.20%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Y-mAbs Therapeutics' stock price today? One share of YMAB stock can currently be purchased for approximately $4.55. How much money does Y-mAbs Therapeutics make? Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $198.70 million and generates $34.90 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis. How many employees does Y-mAbs Therapeutics have? The company employs 148 workers across the globe. How can I contact Y-mAbs Therapeutics? Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com. This page (NASDAQ:YMAB) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.